X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs ASTRAZENECA PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. ASTRAZENECA PHARMA WOCKHARDT LTD./
ASTRAZENECA PHARMA
 
P/E (TTM) x -18.8 117.9 - View Chart
P/BV x 3.1 16.8 18.4% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 WOCKHARDT LTD.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
ASTRAZENECA PHARMA
Mar-14
WOCKHARDT LTD./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1291,285 87.9%   
Low Rs627634 98.9%   
Sales per share (Unadj.) Rs363.1189.6 191.5%  
Earnings per share (Unadj.) Rs-20.4-0.2 10,042.7%  
Cash flow per share (Unadj.) Rs-7.03.8 -181.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.868.6 439.7%  
Shares outstanding (eoy) m110.5525.00 442.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.45.1 47.8%   
Avg P/E ratio x-42.9-4,712.7 0.9%  
P/CF ratio (eoy) x-125.9249.6 -50.4%  
Price / Book Value ratio x2.914.0 20.8%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,06323,988 404.6%   
No. of employees `0006.81.6 434.1%   
Total wages/salary Rs m9,6651,605 602.3%   
Avg. sales/employee Rs Th5,931.83,040.2 195.1%   
Avg. wages/employee Rs Th1,428.11,029.2 138.7%   
Avg. net profit/employee Rs Th-334.0-3.3 10,229.5%   
INCOME DATA
Net Sales Rs m40,1464,740 847.0%  
Other income Rs m1,14392 1,240.5%   
Total revenues Rs m41,2894,832 854.5%   
Gross profit Rs m128-130 -98.6%  
Depreciation Rs m1,489101 1,471.6%   
Interest Rs m2,2530-   
Profit before tax Rs m-2,472-139 1,779.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m-2115 -4,147.3%   
Profit after tax Rs m-2,260-5 44,408.6%  
Gross profit margin %0.3-2.7 -11.6%  
Effective tax rate %8.5-3.7 -233.1%   
Net profit margin %-5.6-0.1 5,243.0%  
BALANCE SHEET DATA
Current assets Rs m46,1602,726 1,693.1%   
Current liabilities Rs m19,2582,435 790.9%   
Net working cap to sales %67.06.1 1,090.0%  
Current ratio x2.41.1 214.1%  
Inventory Days Days10174 136.6%  
Debtors Days Days9441 230.7%  
Net fixed assets Rs m40,1651,035 3,879.6%   
Share capital Rs m55350 1,105.4%   
"Free" reserves Rs m32,814942 3,482.0%   
Net worth Rs m33,3671,716 1,944.5%   
Long term debt Rs m31,9030-   
Total assets Rs m89,6874,156 2,158.0%  
Interest coverage x-0.1NM-  
Debt to equity ratio x1.00-  
Sales to assets ratio x0.41.1 39.2%   
Return on assets %0-0.1 7.0%  
Return on equity %-6.8-0.3 2,283.8%  
Return on capital %-0.30-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m9,121375 2,434.8%   
Fx outflow Rs m2,133470 453.7%   
Net fx Rs m6,988-96 -7,313.0%   
CASH FLOW
From Operations Rs m-2,695-8 33,267.9%  
From Investments Rs m-6,863-146 4,710.2%  
From Financial Activity Rs m12,545862 1,455.0%  
Net Cashflow Rs m3,010709 424.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.3 0.3 766.7%  
FIIs % 7.7 15.7 49.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   67,757 12,856 527.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jan 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - AUROBINDO PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS